LISINOPRIL-DRLA lisinopril 2.5mg (as dihydrate) tablet blister pack

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

Lisinopril dihydrate

Disponibbli minn:

Dr Reddys Laboratories Australia Pty Ltd

INN (Isem Internazzjonali):

Lisinopril dihydrate

Fuljett ta 'informazzjoni

LISINOPRIL-DRLA
CONSUMER MEDICINE INFORMATION
COMMERCIAL-IN-CONFIDENCE
1
LISINOPRIL-DRLA 2.5
LISINOPRIL-DRLA 5
LISINOPRIL-DRLA10
LISINOPRIL-DRLA 20
Lisinopril Tablets
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
THIS LEAFLET ANSWERS SOME COMMON QUESTIONS ABOUT LISINOPRIL-DRLA. IT
DOES NOT CONTAIN
ALL THE AVAILABLE INFORMATION.
It does not take the place of talking to your doctor or pharmacist.
All
medicines
have
risks
and
benefits.
Your
doctor
has
weighed
the
risks
of
you
taking
LISINOPRIL-DRLA against the benefits they expect it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR
OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again.
WHAT LISINOPRIL-DRLA IS USED FOR
LISINOPRIL-DRLA lowers high blood pressure, called hypertension. It is
also used to treat heart
failure and patients who have just had a heart attack. LISINOPRIL-DRLA
belongs to a group of
medicines called ACE inhibitors.
BEFORE YOU TAKE LISINOPRIL-DRLA
DO NOT TAKE LISINOPRIL-DRLA IF:
You have taken any medicines called „ACE- inhibitor‟ for high
blood pressure or heart failure
before, which caused your face, lips, tongue, throat, hands or feet to
swell up, or made it hard for
you to breath.
If
you
have
had
an
allergic
reaction
to
an
ACE
inhibitor
before,
you
may
be
allergic
to
LISINOPRIL-DRLA.
_ _
If you have an allergy to LISINOPRIL-DRLA or any of the ingredients in
LISINOPRIL-DRLA
TABLETS listed at the end of this leaflet.
You are pregnant or breast-feeding.
You have a history of the swelling of the face, lips, tongue, throat,
hands or feet, for no apparent
reason.
The package is torn or shows signs of tampering.
LISINOPRIL-DRLA
CONSUMER MEDICINE INFORMATION
COMMERCIAL-IN-CONFIDENCE
2
The expiry date (EXP) printed on the pack has passed. If you take this
medicine after the expiry
date has passed, it may not work as well.
BEFORE YOU START TO TAKE IT:
_ _
TELL YOUR DOCTOR:
1.
IF YOU INTEND TO BECOME PREGNANT OR INTEND TO BREAST-FEED
2.
IF YOU SUFFER FROM:

Kidney disease

Karatteristiċi tal-prodott

PRODUCT INFORMATION
LISINOPRIL –DRLA TABLETS 2.5 MG
LISINOPRIL –DRLA TABLETS 5 MG
LISINOPRIL –DRLA TABLETS 10 MG
LISINOPRIL –DRLA TABLETS 20 MG
Lisinopril Tablets
Dr Reddy’s Laboratories (Australia) Pty Ltd
NAME OF THE MEDICINE:
Lisinopril dihydrate
CHEMICAL NAME: (S)-1-[N
2
-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate
MOLECULAR FORMULA: C
21
H
31
N
3
O
5 2H
2
O.
MW: 441.53
CAS NO: [83915-83-7]
DESCRIPTION:
A
synthetic
peptide
derivative,
Lisinopril
dihydrate
is
an
oral,
long
acting
angiotension
converting enzyme inhibitor. It is a lysine analogue of enalaprilat
(active metabolite of enalapril).
Lisinopril dihydrate is white to off-white crystalline powder that is
soluble in water, sparingly
soluble in methanol and practically insoluble in ethanol.
LISINOPRIL TABLETS INCLUDE THE FOLLOWING INACTIVE INGREDIENTS: Calcium
Hydrogen Phosphate,
Mannitol, Starch-Maize and, Magnesium Stearate
The 5mg, 10mg & 20mg tablets also include Iron Oxide Red (C177491).
PHARMACOLOGY:
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the
angiotensin converting enzyme
(ACE)
that
catalyses
the
conversion
of
angiotensin
I
to
the
vasoconstrictor
substance,
angiotensin II. Angiotensin II also stimulates aldosterone secretion
by the adrenal cortex.
Inhibition of ACE results in decreased concentrations of plasma
angiotensin II which results in
decreased vasopressor activity and to decreased aldosterone secretion.
The latter decrease may
_Dr Reddy’s Laboratories (Australia) Pty Ltd _
_Lisinopril-DRLA tablets _
_Product Information v2 080610 _
Page
2 of 19
result in a small increase of serum potassium. In hypertensive
patients with normal renal function
treated with lisinopril alone for up to 24 weeks, the mean increase in
serum potassium was
approximately 0.1 mmol/L; however, approximately 15% of patients had
increases greater than
0.5 mmol/L and approximately 6% had a decrease greater than 0.5
mmol/L. In the same study,
patients treated with lisinopril and hydrochlorothiazide for up to 24
weeks had a mean d